Morgan Stanley Targets 2026 for Crypto Trading Launch on E*Trade

Premium Market Analysis

Gain exclusive access to institutional investment strategies

Ethical breaches cause leadership disruption, boosting investor confidence despite sales challenges.

Kohl's Fires CEO Ashley Buchanan Over Vendor Misconduct

Dow Jones

S&P 500

NASDAQ

Market Insights - May 2, 2025

Major pharmaceutical companies showcased robust Q1 2025 results, driven by rebounding product demand and strategic innovations. Eli Lilly's EPS rose to $3.34 on a non-GAAP basis, significantly bolstered by recent acquisitions. BioMarin posted a 15% YoY revenue increase, supported by strong performance in key drug lines, and reaffirmed optimistic full-year guidance.

Amneal Pharmaceuticals saw a 5% revenue growth, transitioning from a prior net loss to net income. Ardelyx achieved a notable 61% YoY increase in total revenue, fueled by strong IBSRELA product sales for irritable bowel syndrome management. Amgen exceeded expectations with an adjusted EPS of $4.90, reflecting effective sales and operational strategies.

BioMarin advanced its clinical pipelines with positive updates on critical drug studies, enhancing future growth prospects. Phathom Pharmaceuticals announced inducement grants to their new Head of Sales, signaling structural expansion. These developments, along with strong earnings, highlight the sector's innovation and strategic momentum.

May 2, 2025

Sign up for our free newsletters